Title II: Research involving the human person

Research involving the following products is subject to express authorisation from the Director General of the Agence nationale de sécurité du médicament et des produits de santé: 1° Organs and tissues of human origin and labile blood products ; 2° Cells of human origin and the cell therapy preparations referred to in Article L. 1243-1 ; 3° Xenogenic cell therapy preparations mentioned in 13° of Article L. 5121-1; 4° Medical…

The application for authorisation relating to the research mentioned in 1° of Article L. 1121-1 concerning the products mentioned in Article R. 1125-7 is sent to the Director General of the Agence nationale de sécurité du médicament et des produits de santé, who decides on the admissibility of the application, ensuring that the application contains all the information. He will acknowledge receipt to the sponsor and notify him of the…

When the application concerns the organs and tissues of human or animal origin mentioned in 1° and 6° of Article R. 1125-7, and the cell therapy preparations mentioned in 2° of Article R. 1125-7 as well as the xenogenic cell therapy preparations mentioned in 3° of Article R. 1125-7, the Director General of the Agence nationale de sécurité du médicament et des produits de santé sends a copy of the…

The time limits within which the Director General of the Agence nationale de sécurité du médicament et des produits de santé must notify the applicant of his response are set as follows: 1° Sixty days from the date of receipt of the complete dossier for research involving the products mentioned in 4° and 5° of Article R. 1125-7; 2° Ninety days from the date of receipt of the complete dossier…